Servier completes the acquisition of Day One Biopharmaceuticals

Rhea-AI Summary

Servier completed its acquisition of Day One Biopharmaceuticals (Nasdaq: DAWN) on April 23, 2026, for $21.50 per share, implying a total equity value of approximately $2.5 billion.

The deal adds OJEMDATM (tovorafenib), an FDA‑approved therapy for pediatric low‑grade glioma, and a clinical‑stage oncology pipeline including Emi‑Le and DAY301. Ipsen holds rights outside the U.S.

Positive

• Adds FDA‑approved product OJEMDATM (tovorafenib) for pediatric low‑grade glioma
• Transaction values Day One at approximately $2.5 billion total equity
• Expands oncology pipeline to include Emi‑Le (ADC) and DAY301

Negative

• None.

Key Figures

Equity value: $2.5 billion Offer price: $21.50 per share Trial stage: Phase 3 +1 more

4 metrics

Equity value $2.5 billion Total equity value of Servier acquisition of Day One

Offer price $21.50 per share Cash consideration for each Day One common share

Trial stage Phase 3 Servier oncology pipeline includes assets up to Phase 3

Strategic horizon 2030 ambition Servier’s stated goal to strengthen position in rare cancers by 2030

Market Reality Check

Price: $21.53 Vol: Volume 2,789,821 is 1.73x...

high vol

$21.53 Last Close

Volume Volume 2,789,821 is 1.73x the 20-day average of 1,612,241, consistent with ongoing deal-related activity. high

Technical Price at $21.53 is at the 52-week high and above the 200-day MA of $10.65, reflecting the cash offer anchoring valuation.

Peers on Argus

DAWN is roughly flat at +0.19% near its cash deal price, while key biotech peers...

DAWN is roughly flat at +0.19% near its cash deal price, while key biotech peers like AVBP, TNGX, KURA, PRAX and VIR are down between about -0.31% and -3.79%, pointing to deal-specific rather than sector-driven trading.

Previous Acquisition Reports

3 past events · Latest: Mar 06 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Servier buyout announced	Positive	+65.9%	Servier agreement to acquire DAWN for $21.50 per share in cash.
Jan 06	Mersana deal closes	Positive	+1.1%	Completion of Mersana acquisition adding Emi-Le ADC to pipeline.
Nov 13	Mersana deal signed	Positive	-14.4%	Definitive agreement to acquire Mersana with cash plus CVR structure.

Pattern Detected

Acquisition headlines have been important catalysts. When DAWN was the target (Servier offer), the stock moved sharply higher, while DAWN’s own outbound deals for Mersana produced mixed reactions, including one notable selloff.

Recent Company History

Over the past months, DAWN’s story has been dominated by M&A. On Nov 13, 2025, it agreed to acquire Mersana, adding the Emi‑Le ADC but the stock fell 14.41%. Completion of that deal on Jan 6, 2026 saw a modest 1.05% gain. The major inflection came on Mar 6, 2026, when Servier agreed to acquire DAWN for $21.50 per share, driving a 65.88% jump. Today’s completion headline confirms that previously announced transaction.

Historical Comparison

+17.5% avg move · In the past year DAWN issued 3 acquisition-related updates, with an average move of 17.51%. Today’s ...

acquisition

+17.5%

Average Historical Move acquisition

In the past year DAWN issued 3 acquisition-related updates, with an average move of 17.51%. Today’s closing-of-deal headline mainly formalizes the large repricing that occurred on the initial Servier offer.

DAWN first expanded via acquiring Mersana, then became a target itself. The current news marks the transition from an announced Servier tender offer to completed ownership, finalizing DAWN’s shift into a wholly owned unit.

Market Pulse Summary

This announcement confirms Servier’s acquisition of Day One Biopharmaceuticals for $21.50 per share,...

Analysis

This announcement confirms Servier’s acquisition of Day One Biopharmaceuticals for $21.50 per share, valuing the deal at about $2.5 billion. It finalizes a process first signaled by the March tender offer and cements OJEMDA and the broader rare-cancer pipeline within Servier’s portfolio. Historically, DAWN’s acquisition headlines have driven sizable moves, especially when it was the target. Investors tracking this situation typically focus on deal-close mechanics and any remaining corporate actions tied to the transaction.

Key Terms

pediatric low-grade glioma, tender offer, fda-approved, antibody drug conjugate (adc), +1 more

5 terms

pediatric low-grade glioma medical

"tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma."

Pediatric low-grade glioma is a slow-growing brain tumor found in children and teenagers that originates from the brain’s support cells and is generally less aggressive than high-grade tumors. It matters to investors because development or approval of diagnostics, drugs, or devices for these tumors can create steady, long‑term revenue opportunities and affect clinical trial timelines, regulatory risk and reimbursement — similar to investing in a product that serves an ongoing maintenance need rather than a one-time fix.

tender offer financial

"completion of the tender offer to acquire all of the issued and outstanding shares"

A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.

fda-approved regulatory

"OJEMDATM (tovorafenib), an FDA-approved medicine in pediatric low-grade glioma"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

antibody drug conjugate (adc) medical

"Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC)"

A antibody drug conjugate (ADC) is a targeted medicine that combines an antibody, which seeks out specific cells, with a potent drug payload so the treatment delivers its toxic effect directly to diseased cells while sparing most healthy tissue—think of a guided missile carrying a small explosive. Investors care because ADCs can offer breakthrough therapies with high market value, but their worth depends heavily on clinical trial results, manufacturing complexity and regulatory approval, which create both upside and risk.

phase 3 medical

"The transaction also strengthens Servier's oncology pipeline from early clinical to Phase 3."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. Not financial advice.

• Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDA^TM in the U.S. in pediatric low-grade glioma. 
• Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unmet needs. 
• Transaction represents total equity value of approximately $2.5 billion.

SURESNES, France, April 23, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share. The acquisition strengthens Servier's leadership in low-grade glioma and expands the Group's position in oncology with the addition of a marketed product and pipeline focused on rare cancers.

"This acquisition represents a significant step forward for Servier as part of our 2030 ambition to strengthen our position in rare cancers, and more specifically in pediatric low-grade glioma," said Olivier Laureau, President of Servier. "Integrating Day One's scientific and clinical capabilities will enhance our Group's ability to support long-term innovation and translate science into meaningful medicines for children and families affected by rare cancers."

Day One's portfolio includes OJEMDA^TM (tovorafenib), an FDA-approved medicine in pediatric low-grade glioma, the most common form of childhood brain tumor. Day One already markets the product in the United States and has licensed the rights outside the U.S. to Ipsen.

The transaction also strengthens Servier's oncology pipeline from early clinical to Phase 3. In addition to tovorafenib, which is being investigated in additional indications, Day One's pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers. 

"Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence in oncology in the U.S. and strengthening our ability to deliver for patients," said David K. Lee, Executive Vice President, USA, and CEO, Servier Pharmaceuticals. "Day One is joining us with strong science, an approved medicine, and a team that knows how to turn innovation into real outcomes for patients. This is about combining focus with execution to deliver for patients with rare cancers."

Contacts

Servier Group
Laura Visserias
laura.visserias.part@servier.com  

Servier Pharmaceuticals (U.S.)
Paulina Bucko
paulina.bucko@servier.com 

PDF:  https://mma.prnewswire.com/media/2964183/SERVIER_LONG.pdf
Logo: https://mma.prnewswire.com/media/2766991/5933999/Servier_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/servier-completes-the-acquisition-of-day-one-biopharmaceuticals-302751627.html

SOURCE Servier

FAQ

What did Servier pay per share to acquire Day One Biopharmaceuticals (DAWN) on April 23, 2026?

Servier paid $21.50 per share in the completed tender offer. According to the company, that price corresponds to a total equity value of about $2.5 billion for Day One.

Which marketed product did Servier acquire from Day One Biopharmaceuticals (DAWN) in April 2026?

Servier acquired OJEMDATM (tovorafenib), an FDA‑approved medicine for pediatric low‑grade glioma. According to the company, Day One already markets the product in the United States.

How does the Day One acquisition affect Servier's oncology pipeline and U.S. presence?

The acquisition expands Servier's oncology pipeline with clinical‑stage assets and strengthens U.S. operations. According to the company, the deal adds early‑to‑Phase 3 programs focused on rare cancers.

Who holds rights to tovorafenib outside the United States after the Servier acquisition of DAWN?

Ipsen holds the rights to tovorafenib outside the United States. According to the company, Day One had previously licensed ex‑U.S. rights to Ipsen before the acquisition closed.